Αντισώματα έναντι του La/SSB ανιχνεύονται στον ορό ασθενών με πρωτοπαθή Σύνδρομο Sjogren (ΣΣ) και ΣΕΛ, η πλειονότητα των οποίων στρέφεται έναντι του κύριου B-κυτταρικού επιτόπου 349-364aa. Σκοπός αυτής της μελέτης ήταν η αξιολόγηση των αντι-La/SSB 349-364aa αντισωμάτων στη διάρκεια του χρόνου και οι πιθανές διασταυρούμενες αντιδράσεις που μπορούν να υπάρξουν. Εξετάστηκαν δείγματα ορών 15 ασθενών με ΣΣ και 15 με ΣΕΛ που παρακολουθούσαν για χρονική περίοδο 3 έως 10 ετών, 30 οροί υγιών μαρτύρων και 30 οροί ασθενών με ΣΕΛ αρνητικών για αντι-La/SSB αντισώματα, χρησιμοποιώντας μια ειδική τεχνική ELISA. Τα επίπεδα των αντι-pep349-364 αντισωμάτων σε όλους τους ορούς των ασθενών με ΣΕΛ εμφανίζουν διακυμάνσεις στο χρόνο και κυμαίνονται παράλληλα με τα αντι-dsDNA αντισώματα. Κεκαθαρμένες αντι-pep349-364 IgG που απομονώθηκαν από ορούς ασθενών με ΣΕΛ βρέθηκαν να αντιδρούν με την ιστόνη H1, ενώ απέτυχαν να δώσουν θετική αντιδράση φθορισμού στην αντι-dsDNA μέθοδο Crithidia luciliae, η οποία δεν περιέχει ιστόνες. Πειράματα ανταγωνιστικής αναστολής έδειξαν ότι η ιστόνη H1 μπορεί να αναστείλει πλήρως τη σύνδεση της αντι-pep349-364 IgG στο πεπτίδιο pep349-364. Συμπερασματικά, μια υποκατηγορία ασθενών με ΣΕΛ εμπεριέχει στον ορό τους αλληλεπιδρόντα αντι-ιστόνης H1 αντισώματα και αντι-pep349-364 αντισώματα, τα οποία μπορεί εσφαλμένα να εκληφθούν ως αντι-dsDNA δραστικότητας στις συνήθεις τεχνικές ELISA.
Cross-recognition between histones and La/SSB may account for anti-DNA reactivity in SLE patients

E. Touloupi*, J. G. Routsias* and A. G. Tzioufas*
*Department of Pathophysiology, School of Medicine, National University of Athens, Athens, Greece

Summary
Antibodies to La/SSB are detected in sera of patients with primary Sjogren's syndrome (pSS) and systemic lupus erythematosus (SLE). The vast majority of anti-La/SSB positive sera contain antibodies directed towards a linear B-cell epitope of La/SSB spanning the sequence 349–364aa (pep349–364). The aim of this study was to evaluate the fluctuation of antibody levels to major B-cell epitopes of La/SSB over time and investigate for their possible crossreactions. Sequential sera from 15 SLE and 15 pSS patients, followed from 3 to 10 years were obtained. All patients with SLE were positive for anti-Ro/SSA, anti-La/SSB and anti-dsDNA antibodies and patients with pSS were positive for anti-Ro/SSA and anti-La/SSB antibodies. Sera from 30 patients with SLE without anti-La/SSB antibodies and 30 healthy individuals served as disease and negative control respectively. All sera tested for the presence of anti-pep349–364 antibodies, using a specific ELISA. Specific anti-pep349–364 IgG was purified from sera of SLE patients and evaluated for cross reactivity against dsDNA and histones. In all SLE sera the levels of anti-pep349–364 antibodies varied in time and fluctuated in parallel with anti dsDNA antibodies. Anti-pep349–364 IgG purified from 7 SLE patients. Five out of 7 were found to react with calf thymus DNA in ELISA. All purified (7/7) anti-pep349–364 IgG preparations reacted with histone H1 and failed to produce a positive immunofluorescence pattern in *Crithidia luciliae* anti-dsDNA assay which lacks histones. Competitive inhibition experiments demonstrated that histone H1 could inhibit completely the binding of anti-pep349–364 IgG to pep349–364 while pep349–364 inhibited by 70% the binding of anti-pep349–364 IgG to histone H1. These findings indicate that a subgroup of SLE patients possess cross-reacting anti-histone H1 antibodies and anti-pep349–364 antibodies, which can be faulty considered as anti-dsDNA reactivity in regular ELISA techniques.

Keywords: anti-La/SSB, histones, Sjogren's syndrome, systemic lupus erythematosus, B-cell epitopes

Introduction
La/SSB autoantigen is a 48 kD protein that is localized predominantly in the nucleus. It is a member of the ribonucleoprotein particle Ro/RNP consisting of at least three proteins (La, Ro60, Ro52 kD and one small RNA molecule [1]. Autoantibodies targeting La/SSB protein are often detected in patients with primary Sjogren's Syndrome (pSS) and Systemic Lupus Erythematosus (SLE).

In our previous studies of B-cell epitope mapping of La/SSB autoantigen, we found 4 epitopes, spanning the sequences 147–154 aa, 291–302 aa, 301–318 aa, 349–364 aa of La/SSB [2]. One of these epitopes, the 349–364 a.a. (pep349–364) presented high sensitivity and specificity for the detection of anti-La/SSB antibodies [3]. Furthermore, antibodies targeting the pep349–364 epitope can be detected in the majority of ANA(+) – anti-La/SSB precipitin negative sera, after blocking the anti-idiotypic antibodies with a complementary to the epitope peptide [4].

One of the aims of this study was to determine the fluctuation of antibody levels to major B-cell epitopes of La/SSB over time, in sequential sera from patient with pSS and SLE.
This study revealed that in the majority of SLE patients the autoantibody levels to pep349–364 of La/SSB varied in parallel with antibodies to dsDNA. This prompted us to investigate further this association. Using specific inhibition experiments with affinity purified human autoantibodies, we found that autoantibodies to pep349–364 react strongly with histone H1. This cross-reactivity is responsible for the anti-dsDNA reactivity observed in sera of a subgroup of SLE patients.

Materials and methods

Human sera

Thirty patients with either pSS or SLE and anti-La/SSB antibodies were selected on the basis of the availability of sequential serum samples, covering a period from three to 10 years. The temporal interval between two sequential serum samples was at least six months. Fifteen patients had SLE while 15 patients had pSS. All patients fulfilled the diagnostic criteria for SLE and pSS [5,6]. Thirty sera from healthy individuals and 30 sera from patients with SLE or pSS without anti-La/SSB antibodies served as normal and disease controls, respectively. All sera were taken for diagnostic and research purposes with the full consent of the patients.

Sera were separated from whole blood from selected patients after centrifugation at 3000 g for 10 min and stored at −30°C until testing.

Synthetic peptides

The La/SSB epitopes 349–364 a.a. (GSGKGKQVFQGKK TKF) and 289–308 a.a. (ANNGNLQLRNKEVTWVEVLEG) were purchased, as peptides in their N-acetylated/C-amide form, from Biosynthesis Co, Lewisville, USA. The peptides were purified by High Performance Liquid Chromatography (HPLC) and subjected to amino acid analysis and mass spectrometry (MS) that confirmed their purity and identity. As control peptide the 250–257 a.a.region (IASRYDQL) from Leishmania glycoprotein gp63 was used.

Recombinant La/SSB protein

La/SSB recombinant protein prepared from a La/SSB cDNA as previously described [7] and purified by poly(U)-Sepharose affinity chromatography [8].

Assays for the detection of anti-peptide antibodies

COSTAR high binding microtitre plates were coated overnight at 4°C with 100 µl of the peptide solution at a concentration 5 µg/ml in phosphate buffer pH = 7.2.

The remaining binding sites were blocked with blocking buffer (BB) (BB: 2% bovine serum albumin, 0.1% Tween 20 in PBS) for 1 h at room temperature and were washed with PBS –0.05% Tween 20. Subsequently, sera of patients were added in dilution (1 : 100 in BB) and the plates were incubated overnight at 4°C. This dilution was selected after the initial optimization experiments.

After 5 washes, goat anti-human IgG conjugated to alkaline phosphatase (1 : 3000 in BB) was added. The plates were incubated for 1 h at room temperature followed by washing and addition of 100 µl p-nitrophenol substrate at 37°C. The optical density was evaluated at 405 nm after 20 min.

In order to normalize our OD readings between different ELISA plates, 3 common positive sera and 3 common normal sera were used in each plate. Experiments with OD coefficient variation more than 10% were repeated. All ODs were transformed and expressed as binding units according the formula:

\[
\text{Binding units} = \frac{\text{SampleOD} \times 100}{\text{PosCtrlOD}}
\]

where SampleOD is the OD reading of the current sample and PosCtrlOD is the mean OD of the 3 positive controls in the current ELISA plate. The cutoff value for anti-peptide ELISA was calculated as the mean normal sera Binding Units +3 standard deviations.

Assay for the detection of anti-dsDNA reactivity

Anti-dsDNA ELISA performed according to the method described by Tzioufas et al. [9]. COSTAR high binding microtitre plates were coated with 50 µl of Poly-L-lysine (50 µg/ml) (Sigma, St. Louis, Mo, USA) for 1 h at 37°C. After washing with PBS, the plates were coated overnight at 4°C with 50 µl of DNA (50 µg/ml) (Sigma). Then the plates were washed with PBS and incubated with 50 µl of S1-nuclease (50 IU/ml) (Promega, Madison, WI, USA) for 1 h at 37°C. After washing and blocking the remaining binding sites with 10% Bovine Serum (BS) for 1 h at room temperature, the plates were incubated overnight at 4°C with patients’ sera (1 : 50 in BS) or with purified anti-pep349–364 IgG (5 µg/ml in BS). Afterwards, goat anti-human IgG conjugated to alkaline phosphatase (1 : 3000 in BB) was added. The plates were incubated for 1 h at room temperature followed by washing and addition of 100 µl p-nitrophenol substrate at 37°C. Absorbance of the colour was measured at 405 nm after 20 min.

Isolation and purification of IgG specific for pep349–364 of La/SSB

Specific immunoaffinity column of CNBr activated sepharose 4B was generated by standard methods, using 20 mg of the synthetic pep349–364. IgG from seven sera with high titre of anti-pep349–364 antibodies was purified by protein A Sepharose, concentrated and passed through the peptide immunoaffinity column. The column was washed with PBS and eluted with urea 8 M. The eluate was dialysed.
against PBS, concentrated at about 1 mg/ml and redialysed. Purified IgGs were stored at ~30 °C, until testing. The initial serum volume was about 5 ml and the amount of purified anti-pep349–364 IgG was ranging from 0·5 to 0·7 mg/serum, as evaluated by Lowry assay (DC Protein Assay, Biorad, Hercules, CA, USA). The purification procedure led to approximately 24× increase in specific antibody activity per μg IgG.

**Crithidia luciliae** anti-dsDNA assay

Commercial *Crithidia luciliae* anti-dsDNA assay was used according to manufacturer’s instructions (INOVA Diagnostics Inc, San Diego, CA, USA). Briefly, 50 μl of diluted sera (1 : 150 in PBS) or purified anti-pep349–364 antibodies (7·5 μg/ml in 2% bovine serum albumin/PBS) was added to *Crithidia luciliae* slides. After incubation for 30 min, the slides were washed and 50 μl of FITC/anti-IgG conjugate (INOVA Diagnostics Inc) was added. Subsequently, after 30 min incubation, the slides were washed again and examined through a fluorescent microscope.

**Assays for the detection of anti-histone H1 and anti-La/SSB antibodies**

COSTAR high binding microtitre plates were coated overnight at 4 °C with 100 μl of histone H1 (10 μg/ml, SIGMA, St. Louis, USA) or recombinant La/SSB (2 μg/ml) in carbonate bicarbonate buffer pH 9·3. In case of anti-histone H1 ELISA, the plates were incubated for 1 h at 37 °C with micrococcal nuclease (100 U/ml) (Amersham Biosciences Inc, New Jersey, USA) prior to the addition of blocking buffer, in order to remove any RNA or DNA contaminants.

The same experimental procedure was followed as previously described using anti-pep349–364 IgG (5 μg/ml in BB).

**Inhibition assays**

Inhibition of binding of anti-dsDNA positive sera to DNA using serial concentration of DNA or pep349–364 as inhibitors.

Increasing concentrations ranging from 0 to 10 μg/ml of S1 nuclease pretreated DNA or pep349–364 were mixed with human anti-dsDNA serial positive sera dilution. The mixtures were incubated for 3 h at room temperature before its application in wells coated with DNA. The procedure continued as for the anti-dsDNA ELISA.

Inhibition of binding of anti-dsDNA positive sera to pep349–364 using serial concentration of DNA as inhibitor

Several concentrations ranging from 0 to 10 μg/ml of S1 nuclease pretreated DNA were mixed with anti-pep349–364 IgG and the mixtures incubated for 3 h at room temperature before its application in wells coated with calf thymus DNA. The procedure continued as for anti-dsDNA ELISA.

**Inhibition of binding of anti-pep349–364 IgG to histone H1 using histone H1 or pep349–364 as inhibitor**

Serial concentrations of histone H1 or pep349–364 ranging from 0 to 10 μg/ml were mixed with anti-pep349–364 IgG and the mixtures were incubated for 3 h at room temperature, before its application in ELISA wells coated with histone H1. The procedure continued as for histones H1 antiantibody ELISA.

**Inhibition of binding of anti-pep349–364 IgG to pep349–364 using histone H1 as inhibitor**

Increasing concentrations of histone H1 ranging from 0 to 10 μg/ml were mixed with anti-pep349–364 IgG and the mixtures were incubated for 3 h at room temperature before its application in ELISA plates coated with pep349–364. The procedure continued as for the anti-pep349–364 assay.

**Results**

**Antibody response to epitope pep349–364 of La autoantigen**

One hundred and fifty serial samples from 30 anti-La/SSB positive patients (15 with SS and 15 with SLE) were tested against pep349–364. Analysis of the data showed that: 85% of patients sera had antibodies against the peptide pep349–364(data not shown) and that the antibodies to pep349–364 appeared early in the disease course, exhibiting variations which did not correlated with the clinical picture of SLE patients, the clinical picture of SS patients, or the duration of the disease (Fig. 1).

The anti-pep349–364 antibody titre varies in parallel to anti-dsDNA titre over time

We evaluated whether the titre of antibodies against pep349–364 correlated with anti-dsDNA antibodies. It was found that the titre of antibodies against pep349–364 of La/SSB varied in parallel with anti-dsDNA antibody titre in all 15 SLE sera tested, indicating an association between the two autoantibody specificities (Fig. 2). The titre
of antibodies against epitope pep289–308 of La/SSB, however, followed the anti-recLa/SSB pattern but not the anti-dsDNA pattern, in the majority of sera tested (Fig. 2).

Cross-reactivity between anti-dsDNA and anti-pep349–364 antibodies

To clarify whether the apparent correlation between the titres of anti-pep349–364 and anti-dsDNA antibodies is due to cross recognition of the two autoantigens, specific inhibition experiments were performed. These experiments revealed that anti-dsDNA serum activity could be inhibited by either dsDNA or pep349–364 peptide at percentages as high as 90% and 95%, respectively (at an inhibitor concentration of 5 µg/ml) (Fig. 3).

Similarly, the binding of autoantibodies to pep349–364 could be inhibited by either dsDNA or pep349–364 peptide with a maximum inhibition rate of 70% and 72%, respectively (at an inhibitor concentration of 5 µg/ml) (Fig. 3).

Cross-reactivity between anti-pep349–364 and anti-dsDNA is probably due to interactions with histones which are present in the dsDNA preparations

In order to study further the interaction of autoantibodies with pep349–364 and dsDNA antigens, we performed

---

**Fig. 1.** Antibody responses against pep349–364 for 12 representative patients. The x-axis holds the sequential patient sera sorted by the collection time (e.g. D1 the first serum collected, D2 the second serum collected, etc.), while the z-axis represents the 12 different patients (P1 to P12). Patients P1-P4, P5-P8 and P9-P12 participate with 5 (D1-D5), 6 (D1-D6) and 7 (D1-D7) sequential sera, respectively. The antibody responses appear early in the disease course, vary in time and could not be correlated with the duration of the disease.

**Fig. 2.** Combined antibody reactivity against pep349–364, pep289–308, recLa/SSB and dsDNA for 9 representative patients. The titre of antibodies against pep349–364 of La/SSB, varied in parallel with the titre of anti-dsDNA antibodies, in serial sera from 15 SLE patients. Data for 9 representative series of sera are presented in the Figure.
experiments, using affinity purified anti-pep349–364 autoantibodies.

All purified anti-pep349–364 antibodies exhibited high reactivity against pep349–364, as expected. On the contrary, purified anti-pep349–364 did not react with poly L-lysine used to coat DNA ELISA plates (data not shown).

Five of seven purified anti-pep349–364 IgG preparations, obtained from SLE patients, also recognized dsDNA, further supporting the cross-reaction hypothesis. None of the 3 normal IgG, used as control, reacted with either dsDNA or pep349–364 (Fig. 4).

Purified anti-pep349–364 antibodies fail to react with dsDNA in a *Crithidia lucilieae* immunofluorescence assay

*Crithidia lucilieae* protozoa contain exclusively double-stranded kinetoplast DNA and lack histone molecules.

26-6% and percentages of positively/negatively charged amino acids: pos/neg pep349–364 = 31%/0% versus pos/ neg histoneH1 = 28%/3%), we investigated whether histone H1 is indeed responsible for the observed cross-reactivity.

All purified pep349–364 antibody preparations were tested and found to bind histone H1 on the ELISA plate (Fig. 4). Even the two anti-pep349–364 antibody preparations which did not recognized dsDNA in ELISA, reacted strongly with histone H1. Moreover, all purified anti-pep349–364 IgGs demonstrated higher reactivity against H1 histone, compared to dsDNA.
Although some investigators claim that *Crithidia* actually possess some kinetoplast associated proteins with common to histone features, this microorganism is a good substrate to study the proposed histone-H1 mediated cross-reactions. Purified anti-349–364 antibodies failed to produce a positive immunofluorescence pattern in *Crithidia luciliae* dsDNA assay, contrary to anti-dsDNA reference sera (Fig. 6). These results further support the suggested histone-contaminant recognition by anti-349–364 antibodies.

**Purified anti-349–364 antibodies specifically recognize histone H1**

As all purified pep349–364 antibody preparations were found to bind histone H1 in ELISA, we sought to study the specificity of this reaction with inhibition experiments. Thus, the binding of purified anti-349–364 to histone H1 was inhibited up to 93% by histone H1 in homologous inhibition experiments (Fig. 7b). The cross reactivity between pep349–364 and histone H1 was apparently confirmed by heterologous inhibition experiments. In this regard, H1 histone was able to block the binding of anti-349–364 antibodies to pep349–364 at 70–90% in a concentration as low as 0.5 µg/ml (Fig. 7a).

The reaction between anti-pep346–364 antibodies and histone H1 was also inhibited by 30–70%, with soluble pep349–364 as inhibitor, at a concentration of 5 µg/ml (Fig. 8). Thus, a 10 fold higher concentration of soluble pep349–364 (as compared with histone H1) is required to achieve lower heterologous inhibition values in anti-
One of the aims of this study was to investigate the relationship of the antibodies titres against B-cell epitope pep349–364 a.a. of the La/SSB autoantigen with the serological picture of patients, during the course of the disease. It was demonstrated that the antibody response against the epitope 349–364 a.a. of La/SSB varied over time and did not correlate with the clinical picture of patients. Both anti-epp349–364 and anti-eppep289–308 antibodies were found to appear early in the disease course, which is in agreement with recent findings suggesting that in Lupus patients, anti-La antibodies develop up to nine years before the disease onset (mean = 3.3 years before) [10]. However, it was unexpectedly found that in Lupus sera anti-pep349–364 antibody titres fluctuated in parallel with anti-dsDNA antibodies, over the time. Specific inhibition experiments suggested that a true cross reactivity between anti-pep349–364 and anti-dsDNA antibodies indeed occur.

The supposed cross reaction between anti-pep349–364 and anti-dsDNA antibodies seems peculiar for at least two reasons: First, the physicochemical properties of pep349–364 a.a. and dsDNA are extremely different, pep349–364 is highly positively charged, while dsDNA is highly negatively charged. Second, the synthetic peptide antigen lacks post-translational modifications, such as phosphorylation that could explain the observed cross-reaction (e.g. through the negatively charged phosphate groups). Calf thymus dsDNA preparations that widely used in dsDNA ELISA, contains approximately 3% histones. Purcell et al. [11] have demonstrated that even such low level contaminants might be responsible for the antigenic recognition of a given sample. Studying the physicochemical properties of histones, we found certain similarities between pep349–364 a.a. and H1 histone. All purified anti-pep349–364 IgGs recognized histone H1 and this recognition could be specifically inhibited by both pep349–364 and histone H1. On the other hand, the same antibodies gave almost no reaction in a dsDNA immunofluorescence assay based on the protozoa Crithidia lucilaiace that lacks histone molecules, further supporting our contaminant (histone H1) recognition hypothesis.

Structurally, the histone core consists of H2A, H2B, H3 and H4 histone, while histone H1 is located near the DNA linker region, bridging neighbouring nucleosomes [12]. Because histone H1 is localized at the outer face of the nucleosome, it may be more accessible to antibodies than the remaining histones. Actually in SLE, histone H1 has been considered as an autoantigen and has been implicated as the major target protein accounting for the Lupus Erythematosus Cell (L.E.C) phenomenon [12–14]. Although anti-histone H1 antibodies are very common in SLE, they are also found in other systemic autoimmune diseases, including SS and RA [15]. The presence of high antibody levels to histone H1 in SLE patients with a positive LEC phenomenon indicates serologically and clinically active disease with major organ involvement, particularly glomerulonephritis.

Despite the fact that anti-La/SSB and anti-histone antibodies cross recognize common antigenic structures, it is inquisitive that anti-La/SSB antibodies are not commonly found in SLE sera. Thus, our observation is valid only for a limited proportion of SLE sera, which contain anti-La/SSB antibodies. On the other hand, it is possible that the presence of anti-La/SSB antibodies in SLE is underestimated. This assumption is supported by two observations. First, it is has been observed that the detection of anti-La/SSB antibodies with CIE underestimates their prevalence, since a significant proportion of anti-La/SSB antibodies are nonprecipitating in CIE [16]. Secondly, the vast majority of ANA positive−anti-La negative SLE sera (that most likely possess also anti-dsDNA or/and anti-histone antibodies) may contain antibodies to pep349–364 of La/SSB, which cannot be detected by conventional CIE, as they are masked by anti-idiotypic antibodies [4].

Our observation that the dsDNA used in ELISA technique may lead to false positive results, emphasize the need for re-evaluation the assays used for anti-dsDNA antibody detection. In this regard, sera containing multiple anti-nuclear antibody specificities should be evaluated by immunofluorescence, using as substrate the protozoa Crithidia lucliae [17]. This method displays high specificity in the identification of anti-dsDNA antibodies. Most importantly, the kineoplast DNA (kDNA) of Crithidia lucilaiace does not contain histones nor single stranded DNA [17,18]. In our experiments Crithidia lucilaiace kDNA gave almost no reaction with the purified anti-pep349–364 antibodies unlike the reaction observed in the classical dsDNA ELISA.
Taken together, our findings show that antibodies to the La/SSB B-cell major autoepitope react with histone H1. This cross-reaction may account for the anti-dsDNA reactivity observed in a subgroup of SLE patients, when commercially available dsDNA is used in the ELISA technique.

Acknowledgements

The authors would like to thank Professor Haralampos M. Moutsopoulos for a thorough review of the manuscript and helpful suggestions and Katerina Theofillopoulou for performing the Crithidia luciliae immunofluorescence assays.

References